Tokyo - Delayed Quote JPY
AnGes, Inc. (4563.T)
64.00
-1.00
(-1.54%)
At close: 3:30:00 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ei Yamada M.D., Ph.D. | CEO, President & Representative Director | -- | -- | 1950 |
| Mr. Naoya Sato | Director of Corporate Development & Director | -- | -- | 1960 |
AnGes, Inc.
Saito Bio-Incubator
1st Floor 7-7-15, Saito-asagi
Ibaraki, 567-0085
Japan
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 55
Description
AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-?B Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.
Corporate Governance
AnGes, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 7, 2025 at 6:00 AM UTC - August 12, 2025 at 6:00 AM UTC
AnGes, Inc. Earnings Date
Recent Events
Recent Events Information Not Available